Full-Time

Medical Education & Medical Affairs Manager

Oncology

Posted on 9/6/2025

Deadline 10/5/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Madrid, Spain

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Requirements
  • Scientific degree: Medical Doctor, Pharmaceutical or Nature Science university degree.
  • Deep knowledge of the therapeutic area.
  • Strength in research and interpretation of medical data (including statistics).
  • +3 years of relevant work experience in Medical Affairs/Medical Education or similar functions.
  • Strong scientific acumen and communication skills in order to be accepted by Leading Specialists in peer-to-peer relationship.
  • Highly focused customer with an awareness of the importance of business results.
  • Innovative with the ability to coordinate and drive a complex and changing environment.
  • Awareness of, and adherence to, Johnson & Johnson Credo values and International Health Care Business Integrity Guide.
Responsibilities
  • To plan, coordinate, and execute Medical Affairs Plan, including research and publication programs conducted by Medical Affairs.
  • To be a therapeutic area scientific expert and to maximize company product value through high scientific quality communication with Leading Specialists.
  • To increase awareness and understanding of Janssen products and processes to internal/external customers.
  • To design local epidemiological studies and scientific publications according to the Company strategy, to assess and discuss the IIS initiatives and other RWE projects.
  • To define and implement medical education strategy for assigned therapeutic areas on behalf of J&J IM Spain, allowing Healthcare Professionals to make more informed decisions for their patient care within the therapeutic and disease areas of strategic importance to the organization.
  • Continuously update their knowledge of products, patient’s treatment trends and clinical activities and studies conducted within the therapeutic area in their region.
  • Provides clinical and technical support to physicians, nurses and other medical professionals on company products and services.
  • Provides feedback to scientific inquiries from the healthcare community and customer concerns about products and their use.
  • Educates customers on clinical use of diagnostic and interventional products.
  • Support PV/Regulatory requests in terms of scientific advice and information to solve complaints/questions from physicians and other medical professionals.
  • To develop the concept and protocol, aligned with strategic interests of the company, and therapeutic area.
  • To support study execution in collaboration with Operational groups (i.e. GCOMAO) and CROs including budget control, contract negotiation and oversight of vendor activities.
  • Participates in the company's drug surveillance program including follow-up of adverse reaction events.
  • Conducts quantitative and qualitative data analysis for Phase IV trials.
  • Facilitates understanding of clinical trial data.
  • To ensure, coordinate and participate in the publication of results and scientific data.
  • Define and develop Medical Education strategy for defined therapeutic areas as part of the Country Value Team (CVT).
  • Identify Educational needs and build Medical Education Strategy and Medical Education Plan, in close collaboration and with the approval of the Medical Education Steering Committee (MESC).
  • Integrate product evidences and align with unmet medical needs in the assigned therapeutic area.
  • Improve the impact of scientific information on the clinical practices of healthcare professionals.
  • Seek for competitive advantage through analysis of the scientific evidence.
  • Maintain fluent communication and networking with EMEA Medical education leads, and with peers from other countries, in order to ensure alignment, influence EMEA plans, and communicate local needs.
  • Identify and customize scientific statements for the target audience.
  • Align the Medical Education plan to the Life Cycle management of the Therapeutic Area.
  • To evaluate, discuss and follow-up investigator initiated trials in collaboration with Medical Scientific Liaisons/other Medical functions/GCO_MAO, following company procedures.
  • To foster other different ways of scientific collaboration with stakeholders (ie. Data Base Enhancement/Database Profiling/Database research).
  • Support to company commercial objectives, such as marketing and communication strategies i.e. promotional materials & activities, ensuring compliance with the necessary Codes of Practice and Laws governing the promotion and sale of medicines.
  • To work proactively (eg. by initiating discussions around areas of concern) and creatively ensure dissemination and understanding of key company messages, particularly those with scientific, medical or clinical content.
  • To develop and maintain a contact network with Leading Specialists.
  • Understand their needs, key value drivers, practical treatment patterns and scientific activities within therapeutic area.
  • Through scientific interactions, communicate medical benefits of products and contribute to foster innovative approaches.
  • To collaborate with MSL manager and MA TAL in the MSL plan development and implementation of MAF plan in the field.
  • To organize and participate in Advisory Boards in cooperation with other positions in the Marketing/Medical Affairs Department as appropriate.
  • Provides medical and product training and scientific support to marketing and Sales Representatives in coordination with Training/Medical Affairs Department as appropriate.
  • Act as scientific reference for Marketing/Sales Representatives for any scientific query, in collaboration with Medical Information as appropriate.
  • Provision of scientific support to other company departments, including but not restricted to Marketing and Sales Representatives, HEMAR, Government affairs, KAMs, PV, Regulatory and Patient Advocacy.
  • To work closely with the EMEA medical teams (EMAPT) to ensure a free flow of information and ideas between the different teams, while aligning objectives.
  • To work closely with the HEMAR local team to ensure a free flow of information and ideas between the different teams, while aligning objectives.
  • To collaborate, work proactively and lead strategic scientific discussion and training within de CVT.
  • Through scientific interactions, i.e interactions with Leading Specialist and participation in congresses, courses..., gain valuable insight into treatment patterns, and scientific activities in the therapeutic area and provide input to the company Medical Affairs Plan / business decision-making.
  • To develop and manage Key Opinion Leaders with the aim of them becoming product/pathology advocates.
  • Observes and promotes all regulatory requirements as defined in applicable regulations, rules and procedures established by the Company, including but not limited to Health Care Business Integrity and Pharmacovigilance.
  • Report all suspected adverse reactions, serious or non serious, I may be aware of within a maximum of 24 hours after being aware of it and communicate it to the Pharmacovigilance Department.
  • Communicate the medical education plan to all involved functions.
  • Act as a link by communicating regularly between other roles within the medical department e.g. medical information, medical affairs and medical scientific liaison to ensure strategic alignment and consistency of activities.
  • Implement strategy by developing educational materials in association with selected third party partners (e.g. medical education, logistics and delegate handling agencies).
  • Identify/support/educate speakers.
  • Build Medical Education programs with scientific third party.
  • Develop and maintain influencer databases in order to assist with provision of speakers and/or delegates for educational, promotional or advisory board purposes using appropriate systems.
  • Dissemination of approved educational, product and therapy area data to HCPs in face to face or meetings environment.
  • Develop and implement metric systems that monitor “quality” of educational programs and activities to allow for continued improvement for subsequent events.
  • Plan, organize and/or facilitate advisory boards on behalf of the company in strategic therapeutic areas where necessary (using third parties where appropriate) in collaboration with other Medical functions.
  • Establish and nurture key customer relations to broaden contact base and knowledge.
  • Evaluation and management of unrestricted Educational Grants. Assure compliance with all applicable laws, policies, and guidelines; in alignment with therapeutic areas of educational interest and taking budget into consideration.
  • Provide point of contact to align EMEA medical education activities. Influence the EMEA plans in provision of appropriate activities for the local operating company to ensure that the correct educational needs are being met.
  • Partner with Medical Societies and other professional bodies to ensure alignment of J&J Innovative Medicine Spain medical education activities by gaining accreditation.
  • Manage planned expenditure to agreed budgets.
  • Partner closely with Medical Scientific Liaisons and MSL manager to assure appropriate medical plan implementation. According to business needs and experience, serve as MSL team manager, setting objectives, providing leadership to deploy an effective team, and measuring success.
  • Through a thorough understanding of HCC/HCBI, the Code of Practice and local regulations, monitor the content of all educational activities/materials to ensure strict compliance with internal and external regulatory requirements.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI and RYBREVANT are driving near-term oncology growth.
  • IMAAVY and CAPLYTA expand J&J into rare immunology and neuropsychiatry.
  • The Firefly Bio acquisition adds a pan-KRAS oncology platform.

What critics are saying

  • STELARA biosimilar erosion is already cutting a major immunology franchise.
  • Firefly Bio's KRAS platform remains early and can fail clinically.
  • AI surgery and Shockwave launches face adoption, reimbursement, and execution risk.

What makes Johnson & Johnson unique

  • J&J focuses on Innovative Medicine and MedTech after spinning off Kenvue in 2023.
  • Its portfolio spans oncology, immunology, neuroscience, cardiovascular, and surgical robotics.
  • The company combines internal R&D with acquisitions like Abiomed, Shockwave, and Ambrx.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

INACTIVE